NCT07296952 Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)
| NCT ID | NCT07296952 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Chicago |
| Condition | Diabetic Retinopathy (DR) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-02-03 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-02-03 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a a type 3 hybrid effectiveness-implementation pilot study to evaluate the PRONTO-EYE intervention, a rideshare transportation program, in patients with diabetic retinopathy with Medicaid insurance on adherence to ophthalmology visits.
Eligibility Criteria
Inclusion Criteria: * Established patient * Medicaid insurance * History of diabetic retinopathy * Lives within 25 miles of the clinic * English speaking
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07296952 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetic Retinopathy (DR). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07296952 currently recruiting?
Yes, NCT07296952 is actively recruiting participants. Contact the research team at ascanz@uic.edu for enrollment information.
Where is the NCT07296952 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07296952 clinical trial?
NCT07296952 is sponsored by University of Illinois at Chicago. The trial plans to enroll 60 participants.